Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Prognostic significance of CD44 expression in adenocarcinoma of the lung

Clarke, MR and Landreneau, RJ and Resnick, NM and Crowley, R and Dougherty, GJ and Cooper, DL and Yousem, SA (1995) Prognostic significance of CD44 expression in adenocarcinoma of the lung. Journal of Clinical Pathology - Clinical Molecular Pathology, 48 (4). ISSN 1355-2910

[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Aims - To determine whether expression of CD44 in neoplasia is associated with tumour grade, stage and prognosis. Methods - The immunohistochemical expression of CD44 was evaluated using the mouse antihuman monoclonal antibody 3G12 which recognises regions shared by all CD44 isoforms to determine whether expression in formalin fixed, paraffin wax embedded tissue correlates with tumour grade, stage or survival in adenocarcinoma of the lung. Thirty one adenocarcinomas of the lung, 16 T2N0 and 15 T2N1, and their nodal metastases were studied. Results - Of the 31 tumours, 25 were positive for the CD44 antigen. CD44 expression correlated with tumour grade, in that intense staining was seen only in moderately and/or poorly differentiated tumours. CD44 did not correlate with nodal status, tumour size, pleural invasion, angiolymphatic invasion, or host inflammatory response, but did correlate with survival. A median survival of 46 months was observed in patients with moderate to strong CD44 expression compared with 24 months for those with no or weak expression. Nine patients were alive without evidence of disease at a median follow up of 61 months. Six (66%) of these nine patients had strong CD44 expression. This contrasts with strong expression in only three (17%) of the 17 patients dying with a median survival of 28 months. Conclusion - In primary adenocarcinoma of the lung loss of CD44 expression is associated with less favorable outcome and may indicate a more aggressive neoplasm. CD44 may be a useful prognostic marker in lung carcinoma.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Clarke, MR
Landreneau, RJ
Resnick, NM
Crowley, R
Dougherty, GJ
Cooper, DL
Yousem, SAyousem@pitt.eduYOUSEM
Date: 1 January 1995
Date Type: Publication
Journal or Publication Title: Journal of Clinical Pathology - Clinical Molecular Pathology
Volume: 48
Number: 4
DOI or Unique Handle: 10.1136/mp.48.4.m200
Schools and Programs: School of Medicine > Biomedical Informatics
Refereed: Yes
ISSN: 1355-2910
PubMed Central ID: PMC407963
PubMed ID: 16696007
Date Deposited: 04 Oct 2012 21:36
Last Modified: 02 Aug 2020 13:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item